Wall Street Zen Upgrades Zimmer Biomet (NYSE:ZBH) to “Buy”

Zimmer Biomet (NYSE:ZBH) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday, Wall Street Zen reports.

A number of other brokerages have also recently issued reports on ZBH. Stifel Nicolaus upped their target price on shares of Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Citigroup reaffirmed a “neutral” rating on shares of Zimmer Biomet in a research report on Monday, October 5th. BMO Capital Markets restated a “market perform” rating on shares of Zimmer Biomet in a research note on Monday, September 28th. Canaccord Genuity Group raised their target price on shares of Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a report on Monday, August 10th. Finally, Argus reaffirmed a “buy” rating and set a $125.00 target price on shares of Zimmer Biomet in a report on Thursday, October 22nd. Seven investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $104.47.

Zimmer Biomet Stock Up 0.0%

Shares of NYSE ZBH opened at $94.54 on Friday. The firm has a 50 day moving average price of $94.86 and a 200 day moving average price of $91.70. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. Zimmer Biomet has a 52-week low of $79.12 and a 52-week high of $103.70. The stock has a market cap of $18.03 billion, a P/E ratio of 23.00, a P/E/G ratio of 2.27 and a beta of 0.49.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.06. The business had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The business’s revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the business posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Analysts expect that Zimmer Biomet will post 8.54 EPS for the current year.

Insider Buying and Selling

In other news, insider Chad Phipps sold 3,000 shares of the firm’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the sale, the insider directly owned 65,231 shares in the company, valued at $6,415,468.85. This trade represents a 4.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kevin R. Thornal sold 5,691 shares of the business’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The disclosure for this sale is available in the SEC filing. 1.28% of the stock is owned by insiders.

Institutional Investors Weigh In On Zimmer Biomet

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in Zimmer Biomet in the second quarter worth about $1,344,282,000. Primecap Management Co. CA purchased a new position in Zimmer Biomet in the 2nd quarter worth approximately $328,578,000. Bank of America Corp DE bought a new stake in shares of Zimmer Biomet during the second quarter valued at about $187,480,000. Equity Investment Corp bought a new position in shares of Zimmer Biomet in the 2nd quarter valued at approximately $144,748,000. Finally, Legal & General Group Plc acquired a new stake in Zimmer Biomet in the 2nd quarter valued at about $126,167,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.